ImmuCell CorporationICCCNASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank86
3Y CAGR+108.7%
5Y CAGR+9.8%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
+108.7%/yr
vs +23.7%/yr prior
5Y CAGR
+9.8%/yr
Recent acceleration
Acceleration
+85.0pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM17.13%+325.4%
20244.03%+128.1%
2023-14.33%-860.4%
20221.88%-86.6%
202114.02%+30.5%
202010.74%+3.0%
201910.43%+1196.0%
20180.81%-87.7%
20176.56%-63.6%
201618.05%-